Gaurav Narula
A paediatric oncologist at Tata Memorial who led the leukaemia arm of India's first CAR-T trials and runs national childhood leukaemia protocols.
Overview
Gaurav Narula is a paediatric oncologist at Tata Memorial Hospital whose work spans childhood acute lymphoblastic leukaemia protocols adapted to Indian conditions, the Indian Childhood Collaborative Leukaemia group trials and the clinical development of talicabtagene autoleucel (NexCAR19), for which he was an investigator and an author of the published real-world series. He also works on infection control and supportive care in low-resource paediatric oncology.
Pages like this
not linked directly; found by shared links- PersonHasmukh Jain
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel.
- PersonRahul Purwar
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel.
- InstitutionIndian Institute of Technology Bombay
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel.
- IdeaPublic-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000
Shares Talicabtagene autoleucel, Tata Memorial Centre, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- CompanyCipla
Shares ImmunoACT, Talicabtagene autoleucel, CAR-T cell therapy.
- InstitutionAdvanced Centre for Treatment, Research and Education in Cancer
Shares Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel, Tata Memorial Centre.
- CompanyAllotera Therapeutics (formerly Wugen)
- PersonJae H. Park